Journal article
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Abstract
BackgroundFirst- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates of 20–25%, with an unknown impact on survival. Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad …
Authors
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE
Journal
Breast Cancer Research and Treatment, Vol. 108, No. 1, pp. 87–92
Publisher
Springer Nature
Publication Date
March 2008
DOI
10.1007/s10549-007-9584-x
ISSN
0167-6806